tirzepatide dual How does the simultaneous activation of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors alter metabolic signaling pathways in laboratory models? Researchers investigating focus on the This dual Tirzepatide for Diabetes and Weight
Description
doi:10.1093/ndt/gfad009 267

Methane, Motility, and GLP-1 Therapy Methane production is associated with slower intestinal transit and constipation-predominant physiology

At week 88, patients receiving tirzepatide lost an additional 6.7% of their mean body weight from randomization, while patients receiving placebo gained 14.8% of their mean body weight, for a placebo-adjusted net weight change of -21.4%

Gelhorn HL, Bacci ED, Poon JL, Boye KS, Suzuki S, Babineaux SM

Gomez CR (1993) Editorial: time is brain

S.AlshehriK
